IKT Earnings

Quarterly EPS
$-0.17
Q4 2024
$-0.15
Q1 2025
$-0.11
Q2 2025
$-0.13
Q3 2025
$-0.10
Q4 2025
$-0.10
Q1 2026
$-0.11
Q2 2026
$-0.10
Q3 2026
Latest RevenueN/A
Latest Net Income-20467334
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q3 2026-$0.100-20467334—+23.1%
Q2 2026-$0.110-19591231—+0.0%
Q1 2026-$0.100-16380840—+33.3%
Q4 2025-$0.100-12734651—+41.2%
Q3 2025-$0.130-11930280—+80.0%
Q2 2025-$0.110-9915523—+83.3%
Q1 2025-$0.150-13678735—+79.5%
Q4 2024-$0.170-12132577-100.0%+66.7%
Q3 2024-$0.650-5778066——
Q2 2024-$0.660-4958832——
Q1 2024-$0.730-4649635——
Q4 2023-$0.511-4177940——
Inhibikase Therapeutics (IKT) — Earnings